PTCT · NASDAQ
PTC Therapeutics, Inc.
$62.00 +1.34 (+2.13%)
Company overview
PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines for patients with rare disorders. Its portfolio includes commercial products and product candidates in various stages of development, spanning clinical, pre-clinical, and research and discovery stages, with a focus on treatments for multiple therapeutic areas in rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as for the treatment of nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $5.2B
- Employees
- 939
- Headquarters
- Warren, NJ
- Website
- ptcbio.com
- CEO
- Matthew Klein
- Listed
- June 20, 2013
- P/E
- -26.56
- Dividend yield
- 0.00%
Company financials
- Revenue
- $827M
- Gross profit
- $644M
- Operating income
- -$67.7M
- EBITDA
- -$22.2M
- Net income
- -$187M
- EPS
- -$2.33
- Total assets
- $2.9B
- Total debt
- $395M
- Gross margin
- 77.84%
- Net margin
- -22.58%
- Earnings yield
- -3.76%
Showing FY 2025
PTCT
1D
NASDAQ
O63.93H65.00L63.85C64.36+1.34 (+2.13%)Vol363.10K